Jaguar Health (JAGX) and Napo Therapeutics announced that the clinical protocol for Napo’s Phase 2 study to evaluate the efficacy of crofelemer, Jaguar’s novel plant-based anti-secretory prescription drug, for the indication of SBS-IF in adults has received regulatory clearance from health authorities in Italy and Germany, where the trial will be conducted. The study initiated yesterday, February 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health extends collaboration with Streeterville
- Jaguar Health extends collaboration with Streeterville to develop P-300
- Jaguar Health announces first SBS-IF patient dosed in IIT trial of crofelemer
- Jaguar supports evauation of FDA-approved crofelemer for GI issues from GLP-1
- Jaguar Health announces first patient dosed in IIT evaluating crofelemer